PDF(Pubmed)
Abstract：
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety of secukinumab in patients with moderate to severe HS after 16 weeks of treatment, and to explore potential predictors of clinical response to the drug.
METHODS: Multicenter observational retrospective study. Patients treated with secukinumab 300 mg every 2 or 4 weeks who had completed at least 16 weeks of follow-up from nine hospitals based in southern Spain (Andalusia) were included in this study. Treatment effectiveness was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR). Information about adverse events was collected, the therapeutic burden of the patients was calculated as the summation of systemic medical treatments and surgical interventions (excluding incision and drainage) experienced until the start of secukinumab treatment.
RESULTS: Forty-seven patients with severe HS were included for analysis. At week 16, 48.9% (23/47) of patients achieved HiSCR. Adverse events were present in 6.4% (3/47) of the patients. The multivariate analysis showed that female sex and, to a lesser extent, lower body mass index (BMI) and a lower therapeutic burden were potentially associated with a higher probability of HiSCR achievement.
CONCLUSIONS: Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR.
METHODS: Multicenter observational retrospective study. Patients treated with secukinumab 300 mg every 2 or 4 weeks who had completed at least 16 weeks of follow-up from nine hospitals based in southern Spain (Andalusia) were included in this study. Treatment effectiveness was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR). Information about adverse events was collected, the therapeutic burden of the patients was calculated as the summation of systemic medical treatments and surgical interventions (excluding incision and drainage) experienced until the start of secukinumab treatment.
RESULTS: Forty-seven patients with severe HS were included for analysis. At week 16, 48.9% (23/47) of patients achieved HiSCR. Adverse events were present in 6.4% (3/47) of the patients. The multivariate analysis showed that female sex and, to a lesser extent, lower body mass index (BMI) and a lower therapeutic burden were potentially associated with a higher probability of HiSCR achievement.
CONCLUSIONS: Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR.
摘要：
背景：化脓性汗腺炎（HS）是一种慢性炎症性皮肤病。由于其免疫调节特性，生物药物在中度至重度患者的长期抗炎治疗中具有关键作用。这项研究的目的是评估苏金单抗在治疗16周后对中度至重度HS患者的有效性和安全性，并探讨该药物临床反应的潜在预测因素。
方法：多中心观察性回顾性研究。本研究包括来自西班牙南部（安达卢西亚）的9家医院的每2或4周用苏金单抗300mg治疗的患者，这些患者完成了至少16周的随访。使用化脓性汗腺炎临床反应（HiSCR）评估治疗效果。收集有关不良事件的信息，患者的治疗负担计算为在苏金单抗开始治疗之前所经历的全身药物治疗和手术干预(不包括切开和引流)的总和.
结果：纳入47例重度HS患者进行分析。在第16周，48.9%(23/47)的患者达到了HiSCR。不良事件出现在6.4%(3/47)的患者中。多变量分析表明,女性性别,在较小程度上，较低的体重指数(BMI)和较低的治疗负担可能与更高的HiSCR成就概率相关.
结论：苏金单抗治疗重度HS患者的短期有效性和安全性良好。女性性别,较低的BMI和较低的治疗负担可能与实现HiSCR的较高概率相关.
方法：多中心观察性回顾性研究。本研究包括来自西班牙南部（安达卢西亚）的9家医院的每2或4周用苏金单抗300mg治疗的患者，这些患者完成了至少16周的随访。使用化脓性汗腺炎临床反应（HiSCR）评估治疗效果。收集有关不良事件的信息，患者的治疗负担计算为在苏金单抗开始治疗之前所经历的全身药物治疗和手术干预(不包括切开和引流)的总和.
结果：纳入47例重度HS患者进行分析。在第16周，48.9%(23/47)的患者达到了HiSCR。不良事件出现在6.4%(3/47)的患者中。多变量分析表明,女性性别,在较小程度上，较低的体重指数(BMI)和较低的治疗负担可能与更高的HiSCR成就概率相关.
结论：苏金单抗治疗重度HS患者的短期有效性和安全性良好。女性性别,较低的BMI和较低的治疗负担可能与实现HiSCR的较高概率相关.
